Freezing should not be assumed to preserve every nitazene better than refrigeration without analyte-specific evidence. A 2022 method study found generally useful refrigerated stability, inconsistent frozen results and an important problem with 5-amino isotonitazene. The results support checking the actual validation conditions, not declaring freezing harmful for all nitazenes or all postmortem specimens.
A controlled blood experiment, not a decomposition series
Walton, Krotulski and Logan fortified drug-free blood with nine nitazene analytes, including parent drugs and isotonitazene metabolites, at 10 ng/mL. Aliquots of 0.5 mL were stored at −20°C, 4°C or approximately 20°C. Samples were extracted and analyzed in triplicate at baseline, 24 and 48 hours, and 7, 14, 28 and 60 days.
Fresh calibration and controls were prepared for each analysis. Stability required remaining within a 20% concentration-change criterion and meeting the necessary identification and quantitation criteria. The experiment did not reproduce microbial contamination or chemical complexity across a series of decomposed human blood specimens.
The principal findings and their limits
The authors reported refrigerated stability for the tested analytes except 5-amino isotonitazene, and concluded that suspected nitazene blood could generally be refrigerated at 4°C for at least 28 days on the evidence generated. Several analytes showed earlier instability at room temperature. Frozen results were inconsistent, with most parent drugs showing instability after 28 days; the authors called for further assessment.
Those findings do not justify a universal numerical loss correction or a claim that a particular frozen case sample must be inaccurate. Only one fortified concentration and the stated storage conditions were tested. Results at 10 ng/mL do not establish identical behavior near the detection limit, in every container or in every biological matrix.
The problematic 5-amino isotonitazene results require particular care: calibration/control accuracy failed during the stability assessment. The authors suspected poor stability but described that attribution as anecdotal and requiring further work. An assay that fails quantitative criteria cannot supply a reliable degradation curve merely because a signal remains visible.
Processed extracts were a different stability question
The same paper assessed prepared extracts retained in the autosampler. Isotonitazene, protonitazene, etonitazene, clonitazene, flunitazene and N-desethyl isotonitazene met the stated stability conditions for up to 216 hours. The reported interval for 5-amino isotonitazene was 192 hours; metonitazene and 4′-hydroxy nitazene had shorter stability windows.
These autosampler observations concern processed analytical material. They do not extend the storage life of unextracted blood, urine, bile or tissue. Conversely, an acceptable refrigerated blood result does not guarantee that an extract can wait indefinitely before injection.
Other validation exceptions remained relevant
The full assay used LC–tandem quadrupole mass spectrometry. Detection limits were 0.1 ng/mL. Most analytes had a 0.5-ng/mL quantitation limit and a 0.5–50-ng/mL calibration range. For 5-amino isotonitazene, the quantitation limit and lowest calibrator were 1.0 ng/mL.
That metabolite also failed dilution and urine matrix-matching assessments. The authors limited its validated use to undiluted blood. This is an analyte-specific restriction; successful validation of other members of the panel did not remove it.
Why case storage history matters
The authentic casework component contained 171 specimens from 114 selected investigations, including 47 postmortem and 67 driving cases. Specimen storage before analysis varied from less than a month to approximately a year. Those histories exceeded the controlled stability experiment in some instances and did not establish that every authentic result was unaffected by storage.
A report review should distinguish specimen stability, extract stability, valid quantitative measurement and biological interpretation. A detected drug does not by itself establish impairment or cause of death, and a later negative result does not reconstruct an earlier concentration without evidence.
Related examples include GHB change in stored postmortem blood and serial ethanol measurements in a preserved specimen. Their mechanisms and analytes are different; their relevance is the need to examine actual handling evidence.
Primary source
Walton SE, Krotulski AJ, Logan BK. A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography–Tandem Quadrupole Mass Spectrometry (LC–QQQ-MS). Journal of Analytical Toxicology. 2022;46:221–231. https://doi.org/10.1093/jat/bkab117.
Leave a Reply